C12N9/96

STABILIZATION OF OXIDASES BY GLYCINE
20230048008 · 2023-02-16 ·

Described are compositions and methods relating to the stabilization of oxidase enzymes using the amino acid glycine. The compositions and methods allow for drying oxidase-containing compositions with improved enzyme activity yield and long term storage of dried oxidase-containing compositions, in some cases without the need for refrigeration.

STABILIZATION OF OXIDASES BY GLYCINE
20230048008 · 2023-02-16 ·

Described are compositions and methods relating to the stabilization of oxidase enzymes using the amino acid glycine. The compositions and methods allow for drying oxidase-containing compositions with improved enzyme activity yield and long term storage of dried oxidase-containing compositions, in some cases without the need for refrigeration.

Acetolactate decarboxylase variants having improved specific activity

Compositions and methods are provided comprising acetolactate decarboxylase (ALDC) enzyme variants having higher specific activity. Composition and method are provided where the ALDC variants are used in combination with metal ions to further increase stability and/or activity.

Self-assembling protein scaffolds and methods

A protein scaffold includes a plurality of EutM subunits and a multi-enzyme cascade. The multi-enzyme cascade includes a first enzyme attached to the first EutM subunit and a second enzyme attached to the second EutM subunit. The scaffold may be formed by a method that generally includes incubating a plurality of EutM subunits under conditions allowing the EutM subunits to self-assemble into a protein scaffold, attaching a first enzyme of a multi-enzyme cascade to a first EutM subunit, and attaching a second enzyme of the multi-enzyme cascade to a second EutM subunit. The scaffold may be self-assembled in vivo or in vitro. Each enzyme may be, independently of any other enzyme, attached to its EutM subunit in vivo or in vitro. Each enzyme may be, independently of any other enzyme, attached to its EutM subunit before or after the scaffold is assembled.

Self-assembling protein scaffolds and methods

A protein scaffold includes a plurality of EutM subunits and a multi-enzyme cascade. The multi-enzyme cascade includes a first enzyme attached to the first EutM subunit and a second enzyme attached to the second EutM subunit. The scaffold may be formed by a method that generally includes incubating a plurality of EutM subunits under conditions allowing the EutM subunits to self-assemble into a protein scaffold, attaching a first enzyme of a multi-enzyme cascade to a first EutM subunit, and attaching a second enzyme of the multi-enzyme cascade to a second EutM subunit. The scaffold may be self-assembled in vivo or in vitro. Each enzyme may be, independently of any other enzyme, attached to its EutM subunit in vivo or in vitro. Each enzyme may be, independently of any other enzyme, attached to its EutM subunit before or after the scaffold is assembled.

STABILIZATION OF OXIDASES BY DRYING UNDER REDUCED PARTIAL OXYGEN PRESSURE
20230041414 · 2023-02-09 ·

Described are compositions and methods relating to the stabilization of oxidase enzymes by heat (or thermal) drying under reduced partial pressure of diatomic oxygen. The compositions and methods allow for dehydration of oxidase-containing compositions with no loss of enzyme activity.

INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-BETA-TRNA SYNTHETASES

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

COMBINATION CANCER IMMUNOTHERAPIES WITH ARGININE DEPLETION AGENTS
20180010114 · 2018-01-11 ·

Provided are arginine depletion agents such as ADI-PEG for use in combination with cancer immunotherapies, for example, immune checkpoint modulators and T-cell adoptive immunotherapies, for treating various cancers. Also provided are related methods, compositions, patient care kits, and cell cultures.

COMBINATION CANCER IMMUNOTHERAPIES WITH ARGININE DEPLETION AGENTS
20180010114 · 2018-01-11 ·

Provided are arginine depletion agents such as ADI-PEG for use in combination with cancer immunotherapies, for example, immune checkpoint modulators and T-cell adoptive immunotherapies, for treating various cancers. Also provided are related methods, compositions, patient care kits, and cell cultures.

Composition for polymerase reaction

Provided are a composition for a polymerase reaction, containing a nucleic acid polymerase and a 2-methacryloyloxyethyl phosphorylcholine (MPC)-containing zwitterionic copolymer detergent, a tube for a polymerase reaction, and a kit for a polymerase reaction. The stability of the composition for a polymerase reaction can be improved and the reliability of the results of polymerase reaction such as nucleic acid polymerization or amplification can be improved.